Brevia Health deepens vaccines expertise with Nick Lowen appointment

Brevia Health has deepened our vaccines expertise with the appointment of Nick Lowen as an Associate with over 30 years’ life sciences experience including serving as Vice President, Commercial Strategic Projects at GSK.  During his time at GSK, Nick successfully led complex negotiations including the introduction of innovative vaccines for the UK and other European markets.  As Vice Chair of the UK Industry Vaccines Group, he oversaw the development of the ABPI position on market access and response to the DHSC CEMIPP report.  Nick joins our senior team of advisers that include Gillian Leng CBE (former CEO, NICE), Jonathan Mogford (former Director of Policy, MHRA) and Mike Thompson MBE (former CEO, ABPI).

Nick trained as a pharmacist and began his career in the NHS.  Before joining the Biopharma industry, he was one of the UK’s first regional NHS Pharmaceutical advisers.

He joined GSK in 1997 where he worked for over 25 years and held a number of senior leadership roles.  During this period, he successfully led complex negotiations including the introduction of innovative vaccines for the UK and other European markets.  As Vice Chair of the UK Industry Vaccines Group, Nick oversaw the development of the ABPI position on market access and response to the DHSC CEMIPP report.

In addition to Vaccines, Nick has therapeutic experience in Neurology, Dermatology, Anti-infectives, Respiratory, Oncology and specialist medicines.

Nick has a passion for delivering marketing and sales excellence across Global, EU and UK Pharmaceutical markets through launching innovative products, life cycle management and building market access.  He has a strong track record managing teams to create and deliver strategic business change in Pharma, including managing the transition to outsource operations in multiple countries, creating business development opportunities, and negotiating and concluding significant business deals.

 

BREVIA HEALTH PROVIDES STRAIGHTFOWARD PUBLIC AFFAIRS AND PUBLIC RELATIONS SUPPORT TO BUSINESSES AND CHARITIES OPERATING IN THE HIGHLY REGULATED UK HEALTHCARE SECTOR

Discover how Brevia can help you and your organisation by viewing our Health services or contacting the Brevia Team on 020 7091 1650 or emailing us at contact@brevia.co.uk

 

 

 

 

 

LATEST NEWS

Energy

Shaping the Future of CfDs: Key Reforms in AR7 Consultation

With the DESNZ consultation on AR7 closing on 21 March 2025, Brevia Energy examines the key proposals that could shape the future of the Contracts for Difference (CfD) regime. From relaxed eligibility requirements for offshore wind, to extended contract terms and new capacity ambitions, these changes could significantly impact the renewable energy sector. Businesses and investors must engage with the consultation to ensure their interests are represented in the evolving energy landscape.

Read More »
Energy

What does the Seventh Carbon Budget mean for the future of hydrogen?

The Climate Change Committee recently published its Seventh Carbon Budget, outlining the UK’s strategic framework for achieving significant emissions reductions over the coming decades. A key takeaway is the downgrading of the CCC’s view on hydrogen for home compared with the Sixth Carbon Budget published in 2020. In this article, Brevia reviews the CCC’s positioning on heat in the Seventh Carbon Budget compared to the Sixth Carbon Budget.

Read More »
Energy

Future of UK Electricity Pricing: Is Zonal Pricing Inevitable?

With a decision on the Review of the Electricity Market Arrangements (REMA) expected imminently, and the intensity around the debate on zonal pricing growing, Brevia’s energy team takes a look at the latest developments, assessing implications, key considerations and expected timelines for businesses to consider in navigating this potential transition.

Read More »